Form 4: STOK CFO Sells Shares for Tax Obligations

Stoke Therapeutics CFO Thomas Leggett sold common stock totaling 4,578 shares to cover tax withholding liabilities related to restricted stock unit vesting.

Summary

• Thomas Leggett, Chief Financial Officer of Stoke Therapeutics, Inc. (STOK), sold a total of 4,578 shares of common stock.
• These sales occurred on March 17, 2026, and March 18, 2026.
• The transactions were mandated by the issuer to satisfy tax withholding liabilities associated with the vesting and settlement of restricted stock units.
• The sales were executed at weighted average prices ranging from $31.2838 to $33.3754 per share.
• Following these transactions, Mr. Leggett directly beneficially owns 10,172 shares of common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive equity compensation and tax obligations, with no inherent positive or negative implications for the company's operational or financial performance.

Industry Context

StockSavvy.ai notes that insider sales to cover tax obligations upon the vesting of restricted stock units are a common and routine occurrence in the biotechnology industry, reflecting standard equity compensation practices rather than a change in management's outlook on the company's prospects.

Stakeholder Impact

• Minimal direct impact on shareholders as these are routine, pre-planned sales for tax purposes and do not indicate a change in company fundamentals or management confidence.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned sale of shares by the CFO to cover tax obligations associated with restricted stock unit vesting. Such transactions are common and do not typically reflect a change in the company's fundamentals or management's long-term outlook. Therefore, it provides no new information that would warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Stoke Therapeutics, STOK, Thomas Leggett, CFO, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Compensation